Aberdeen Group plc Has $31.55 Million Stake in Inspire Medical Systems, Inc. $INSP

Aberdeen Group plc grew its holdings in shares of Inspire Medical Systems, Inc. (NYSE:INSP) by 100.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 243,102 shares of the company’s stock after acquiring an additional 121,741 shares during the quarter. Aberdeen Group plc’s holdings in Inspire Medical Systems were worth $31,547,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of INSP. Quarry LP raised its stake in Inspire Medical Systems by 2,127.3% during the first quarter. Quarry LP now owns 245 shares of the company’s stock worth $39,000 after acquiring an additional 234 shares in the last quarter. Banque Transatlantique SA acquired a new position in Inspire Medical Systems during the first quarter worth about $46,000. Smartleaf Asset Management LLC raised its stake in Inspire Medical Systems by 27.2% during the first quarter. Smartleaf Asset Management LLC now owns 454 shares of the company’s stock worth $71,000 after acquiring an additional 97 shares in the last quarter. Farther Finance Advisors LLC raised its stake in Inspire Medical Systems by 14.6% during the second quarter. Farther Finance Advisors LLC now owns 603 shares of the company’s stock worth $78,000 after acquiring an additional 77 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in Inspire Medical Systems by 253.7% during the first quarter. GAMMA Investing LLC now owns 573 shares of the company’s stock worth $91,000 after acquiring an additional 411 shares in the last quarter. Institutional investors and hedge funds own 94.91% of the company’s stock.

Insider Buying and Selling

In related news, CFO Richard Buchholz sold 11,000 shares of the company’s stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $93.39, for a total value of $1,027,290.00. Following the sale, the chief financial officer directly owned 44,867 shares in the company, valued at $4,190,129.13. This represents a 19.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. KeyCorp downgraded Inspire Medical Systems from an “overweight” rating to a “sector weight” rating in a research note on Tuesday, August 5th. UBS Group set a $89.00 target price on Inspire Medical Systems and gave the stock a “neutral” rating in a research note on Monday, September 22nd. JPMorgan Chase & Co. cut Inspire Medical Systems from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $195.00 to $110.00 in a report on Tuesday, August 5th. Wall Street Zen cut Inspire Medical Systems from a “buy” rating to a “hold” rating in a report on Saturday, July 26th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $150.00 price target on shares of Inspire Medical Systems in a report on Friday. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Inspire Medical Systems has a consensus rating of “Hold” and an average target price of $150.50.

Inspire Medical Systems Price Performance

Shares of INSP stock opened at $75.23 on Monday. The business’s 50 day simple moving average is $84.07 and its 200 day simple moving average is $121.24. Inspire Medical Systems, Inc. has a one year low of $70.77 and a one year high of $216.01. The stock has a market capitalization of $2.22 billion, a PE ratio of 43.49, a PEG ratio of 2.34 and a beta of 1.16.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, August 4th. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.22 by $0.23. Inspire Medical Systems had a return on equity of 10.38% and a net margin of 6.17%.The business had revenue of $217.09 million for the quarter, compared to analysts’ expectations of $214.50 million. During the same period in the prior year, the business posted $0.32 earnings per share. The firm’s revenue was up 10.8% on a year-over-year basis. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS. As a group, research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Inspire Medical Systems announced that its Board of Directors has approved a stock buyback plan on Monday, August 11th that authorizes the company to repurchase $200.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 8.6% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.